Scarica l'app Stockscreener
1.68
2.33%
-0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LXRX Giù?
Forum
Previsione
Frazionamento azionario
Lexicon Pharmaceuticals Inc Borsa (LXRX) Ultime notizie
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug - Yahoo Finance
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo - Bitget
Lexicon brings ACC data showing heart benefits across BMI groups - Stock Titan
Lexicon Pharmaceuticals (LXRX) Receives Reiterated Buy Rating at $6.00 | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851 - TradingView
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 - Yahoo Finance
HC Wainwright remains a buy on Lexicon Pharmaceuticals (LXRX) - MSN
Published on: 2026-03-22 17:56:17 - baoquankhu1.vn
LXRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
Lexicon Pharmaceuticals advances chronic pain treatment options with focus on non opioid innovation - Traders Union
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - MSN
Lexicon Pharma spikes after insider buy - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Growth Value: How does Lexicon Pharmaceuticals Inc compare to its peers2026 EndofMonth & Low Drawdown Investment Ideas - baoquankhu1.vn
Dip Buying: How much upside does Lexicon Pharmaceuticals Inc have2026 PreEarnings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
HC Wainwright raises its price target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and maintains a buy rating - MSN
Lexicon Pharmaceuticals, Inc.Common Stock (NQ: LXRX - The Chronicle-Journal
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ: LXRX) asks holders to double shares, renew equity plans - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK) - The Globe and Mail
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 earnings call transcript - MSN
H.C. Wainwright reiterates Buy on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating - Insider Monkey
Lexicon Pharmaceuticals at Leerink Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
LXRX: Late-stage trials and regulatory milestones drive pipeline progress and strategic partnerships - TradingView
Lexicon Pharmaceuticals (LXRX) to Present Key Findings on Sotagl - GuruFocus
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes - The Manila Times
Diabetes drug sotagliflozin cut low-sugar events, across kidney stages - Stock Titan
Citigroup Raises Price Target for Lexicon Pharmaceuticals (LXRX) - GuruFocus
Citigroup Forecasts Strong Price Appreciation for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock - MarketBeat
Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones - TipRanks
What is HC Wainwright's Estimate for LXRX Q1 Earnings? - MarketBeat
Quarterly Risk: How does Lexicon Pharmaceuticals Inc compare to its peersQuarterly Earnings Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-03-08 - Seeking Alpha
Volume Summary: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteria2025 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
LXRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
Lexicon Pharmaceuticals Q4 2025 earnings preview - MSN
Lexicon Pharmaceuticals 2025 Financial Report: Q4 Loss Narrows, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.8% Following Earnings Beat - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript - Insider Monkey
FY2027 Earnings Forecast for LXRX Issued By HC Wainwright - MarketBeat
Lexicon outlines 2026 milestones as SONATA-HCM enrollment surpasses 50% and cash position is strengthened - MSN
HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment - AOL.com
Lexicon Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
H.C. Wainwright Maintains Buy on LXRX Lexicon Pharmaceuticals Mar 2026 - Meyka
Lexicon Pharmaceuticals 2025 10-K: $49.8M Revenue, $0.14 EPS Loss - TradingView
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates - Bitget
Lexicon Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap DownShould You Sell? - MarketBeat
Lexicon Pharmaceuticals stock price target raised to $6 by H.C. Wainwright - Investing.com Canada
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Lexicon Pharmaceuticals (LXRX) Target Price Raised by HC Wainwri - GuruFocus
Lexicon Pharmaceuticals (NASDAQ:LXRX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Lexicon (LXRX) Q4 2025 Earnings Call Transcript - The Globe and Mail
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):